biostudies-literatureUnknown121(8)Xu Y<h4>Background</h4>Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the efficacy and safety of apatinib in patients with extensive-stage (EC) SCLC who had progressed after two or three previous therapies.<h4>Methods</h4>Eligible patients were histologically confirmed ES-SCLC after two or three previous treatments, including a platinum-based regimen. Patients received apatinib at an initial dose of 500 mg once daily. The primary endpoint was the objective response rate.<h4>Results</h4>Forty patients were enrolled. At the data cut-off time (November 15, 2018), the British journal of cancer640-646https://www.ebi.ac.uk/biostudies/studies/S-EPMC6889407biostudies-literatureApatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.PMC6889407Chen KFan YChen JChen MQin JHan NJin YShi XZhang PLi WLi YXie FHuang ZLu HGong LXu XZhao JXu WYu XXu YfalseApatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.<h4>Background</h4>Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the efficacy and safety of apatinib in patients with extensive-stage (EC) SCLC who had progressed after two or three previous therapies.<h4>Methods</h4>Eligible patients were histologically confirmed ES-SCLC after two or three previous treatments, including a platinum-based regimen. Patients received apatinib at an initial dose of 500 mg once daily. The primary endpoint was the objective response rate.<h4>Results</h4>Forty patients were enrolled. At the data cut-off time (November 15, 2018), the 2019-01-01T00:00:00Z2019 Oct2026-04-29T17:19:35.809Z2020-09-18T07:07:40ZS-EPMC68894073152305810.1038/s41416-019-0583-6